Not All Stabilizers Are Created Equal...And Neither Is All Albumin 

When formulators evaluate excipient options for biologics, the field is wider than serum-derived vs. recombinant albumin. Polysorbates, sugars, synthetic polymers, and other protein stabilizers all compete for the same spot in your formulation. Each comes with tradeoffs. 

The real competition looks like this:

 Where rHSA wins across the field: 

• vs. surfactants — Albumin provides multifunctional protection (shear, oxidation, aggregation, surface adsorption) without the oxidative instability risk that degrades polysorbates over shelf life
• vs. sugars alone — Sugars stabilize by vitrification; they don't bind, carry, or actively protect the biologic the way albumin does. Data shows rHSA + trehalose + F127 dramatically outperforms any single excipient alone
• vs. synthetic polymers — rHSA is biocompatible by design — it is the molecule the body uses to stabilize, transport, and protect proteins in circulation
• vs. plasma HSA — Structural homogeneity, defined Cys34 redox state, no caprylate interference, consistent lot-to-lot performance

The bottom line:

Most excipients protect your biologic from one or two stressors. Recombinant albumin addresses shear stress, freeze-thaw damage, surface adsorption, oxidative degradation, aggregation, and formulation consistency — simultaneously, and with a growing regulatory track record behind it.

Choosing rHSA isn't just upgrading your albumin source.

It's choosing a multifunctional platform excipient with no synthetic tradeoffs.